

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

OC 02120

3157131

<p style="text-align: center;">Licensee</p> <p>1. Riverview Hospital</p> <p>2. 395 Westfield Road P.O. Box 220 Noblesville, IN 46060</p>	<p>In accordance with the letter dated September 4, 2006,</p> <p>3. License number 13-16286-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date October 31, 2010</p> <hr/> <p>5. Pocket No. 030-10729 Reference No.</p>
--	--

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct material permitted by 10 CFR 31.11</p> <p>E. Any byproduct material permitted by 10 CFR 35.500</p> <p>F. Uranium (depleted in uranium-235)</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Prepackaged Kits</p> <p>E. Sealed sources (North American Scientific, Inc. Model No. 3601 and Isotope Products Laboratories Model No. HEG-137)</p> <p>F. Plated metal</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. As needed (not to exceed one curie of I-131)</p> <p>D. As needed</p> <p>E. Total activity not to exceed 1120 millicuries. (Gadolinium-153 not to exceed 250 millicuries per source and cesium-137 not to exceed 30 millicuries per source).</p> <p>F. Two shields, not to exceed 22 kilograms (25 pounds) each</p>
---	--	--

9. Authorized Use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
 - B. Any imaging and localization study permitted by 10 CFR 35.200.
 - C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-16286-01

Docket or Reference Number
030-10729

Amendment No. 27

- D. In vitro studies.
- E. Diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered pursuant to 10 CFR 30.32(g).
- F. For use as shielding in an ADAC Laboratories Attenuation Correction Model MCD/AC Device.

CONDITIONS

R E G

10. Licensed material shall be used only at the licensee's facilities located at 395 Westfield Road, Noblesville, Indiana.
11. The Radiation Safety Officer for this license is Patrick J. Byrne, D.A.B.R.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

Authorized Users

Material and Use

Linda Lau, M.D.	10 CFR 35.100, 35.200, 35.300, 35.500, and 31.11.
Daniel C. Han, M.D.	10 CFR 35.300.
Arve Gillette, M.D.	10 CFR 35.300.
Anthony J. Cossell, M.D.	10 CFR 35.100, 35.200, 35.500, and 31.11.
William E. McGraw, M.D.	10 CFR 35.100 and 35.200.
James E. Currier, M.D.	10 CFR 35.300.
Jianan Graybill, M.D.	10 CFR 35.300.
John Mark Michael, M.D.	10 CFR 35.100, 35.200 and 35.300.
Richard L. Hallett, M.D.	10 CFR 35.100, 35.200 and 35.300.
Peter D. Arfken, M.D.	10 CFR 35.100, 35.200 and 35.300.
John A. Morton, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
Margaret Brengle, M.D.	10 CFR 35.100 and 35.200.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-16286-01

Docket or Reference Number
030-10729

Amendment No. 27

Jeffrey I. Reider, M.D.	10 CFR 35.100 and 35.200.
Homer F. Beltz, M.D.	10 CFR 35.100 and 35.200.
Michael S. Skulski, M.D.	10 CFR 35.100 and 35.200.
Richard T. Beeler, M.D.	10 CFR 35.100, 35.200 and 35.300.
Steven A. Fritsch, M.D.	10 CFR 35.100 and 35.200.
Frank J. Pistoia, M.D.	10 CFR 35.100 and 35.200.
Michael A. Kuharik, M.D.	10 CFR 35.100 and 35.200
Janalyn P. Ferguson, M.D.	10 CFR 35.100 and 35.200.
Jane S. Mitchell, M.D.	10 CFR 35.100 and 35.200.
Jack J. Moss, M.D.	10 CFR 35.100 and 35.200.
Lori J. Wells, M.D.	10 CFR 35.100 and 35.200.
Eric D. Elliott, M.D.	10 CFR 35.100 and 35.200.
Charles A. Lerner, M.D.	10 CFR 35.100 and 35.200.
Thomas Hagman, M.D.	10 CFR 35.100, 35.200 and 35.300.
Brian J. Weigel, M.D.	10 CFR 35.100, 35.200 and 35.300.
Jack M. Drew, M.D.	10 CFR 35.100, 35.200 and 35.300.
David R. Gulliver, M.D.	10 CFR 35.100, 35.200 and 35.300.
J. Michael Phelps, Jr., M.D.	10 CFR 35.100, 35.200, and 35.300 (excluding iodine-131 for thyroid carcinoma).
Timothy L. Davis, M.D.	10 CFR 35.100, 35.200, and 35.300 (excluding iodine-131 for thyroid carcinoma).
Vincent P. Mathews, M.D.	10 CFR 35.100 and 35.200.
Theodore P. Labus, M.D.	10 CFR 35.100, 35.200 and 35.300.
Cristina M. Shinaver, M.D.	10 CFR 35.100, 35.200 and 35.300.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-16286-01

Docket or Reference Number
030-10729

Amendment No. 27

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. Sealed sources containing licensed material shall not be opened or sources removed from source holders by the licensee.
15. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated September 21, 2000 (except Item 12.1); and
- B. Facsimile dated November 20, 2000; and
- C. Letters dated August 2, 2001, August 23, 2001, November 6, 2001, January 14, 2002 (with enclosed close-out survey of old Nuclear Cardiology room), March 26, 2002 (with enclosed close-out survey of old nuclear medicine department), March 28, 2002, and June 9, 2006; and
- D. Facsimile letter dated September 7, 2006.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date NOV 09 2006

By *Toye L. Simmons*
Toye L. Simmons
Materials Licensing Branch
Region III